Aclaris Therapeutics, Inc. (ACRS) Financials
ACRS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 197.4 million | 40.2 million |
2023-09-30 | 218.4 million | 62.0 million |
2023-06-30 | 235.6 million | 55.9 million |
2023-03-31 | 229.7 million | 52.9 million |
ACRS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -7.2 million | 1.3 million |
2023-09-30 | -24.6 million | 5.9 million |
2023-06-30 | -20.9 million | 6.5 million |
2023-03-31 | -26.9 million | 6.8 million |
ACRS Net Income
No data available :(
ACRS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 119.1 million | - | 426000 |
2023-09-30 | 187.0 million | - | 310000 |
2023-06-30 | 210.8 million | - | 458000 |
2023-03-31 | 204.4 million | - | 603000 |
ACRS Shares Outstanding
ACRS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 441000 | 26.6 million | 8.2 million | 4.9 million |
2023-09-30 | 84000 | 23.9 million | 7.1 million | - |
2023-06-30 | 231000 | 25.3 million | 8.3 million | - |
2023-03-31 | 553000 | 22.6 million | 8.8 million | - |
ACRS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 17.6 million | 6.4 million |
2023-09-30 | 9.3 million | 848000 |
2023-06-30 | 1.9 million | 1.6 million |
2023-03-31 | 2.5 million | 1.9 million |
ACRS
Price: $1.36
52 week price:
Earnings Per Share: -1.27 USD
P/E Ratio: -0.74
Exchange: NMS
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 2.0 million
Ebitda: -18.6 millionMarket Capitalization: 88.1 million